DBV Technologies Stock: Share Price, Results and Analysis 2026
This profile covers DBV Technologies (DBV), healthcare — immunotherapy (Viaskin). A French biotech specializing in patch-based immunotherapy (Viaskin, food allergies). 2025: a few million euros in revenue and a net loss of 147 million — a binary bet on approval of the peanut patch.
The data below comes from the latest published financial statements (S&P data verified in November 2026): it covers the last three fiscal years, the dividend policy and the key decision factors for investors.
DBV Technologies Stock Profile
| Company | DBV Technologies |
| Market | Euronext Paris (DBV) — PEA-eligible. |
| ISIN | FR0010417345 |
| Sector | Healthcare — immunotherapy (Viaskin) |
| Reporting currency | US dollars |
| Dividend (latest fiscal year) | no dividend paid |
Results for the Last Three Fiscal Years
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $6M | -$147M |
| 2024 | $4M | -$114M |
| 2023 | $16M | -$73M |
Net cash stands at $188M: a debt-free balance sheet.
Dividend Policy
For the last full fiscal year, the dividend per share was: no dividend paid. Check the ex-dividend schedule (usually announced with annual results) and the applicable taxation: withholding tax in the issuing country, creditable in France within the limits of tax treaties.
Strengths
- A patch technology unique in the world
- Pediatric allergy pipeline
- Net cash of €188M
Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →Points to Watch
- Almost no revenue (pre-commercial stage)
- Net loss of €147M
- Dependence on FDA decisions
Conclusion: DBV Technologies stock is a speculative biotech option, suitable only for very small position sizes.
Reading These Figures Like an Investor
Three habits will help you get the most out of the table above. First, the revenue trend over three fiscal years: steady growth signals a solid franchise, while erosion calls for an explanation (cycle, loss of market share, divestment). Next, conversion into net income: net margin reveals pricing power and cost discipline — compare it from one year to the next rather than between companies. Finally, net cash: a cash-rich balance sheet provides options (buybacks, acquisitions, special dividend), while net debt means checking that interest is covered by operating income. Add to this the dividend yield (dividend divided by share price) and its coverage by earnings: a dividend covered more than twice over can withstand bad years. Taken together, these four indicators turn a profile like this one into a genuine decision-making tool — to be cross-checked with the group’s quarterly reports to spot turning points before the consensus does.
How to Buy DBV Technologies Stock
Open a brokerage account (or a PEA for eligible European listings) with a regulated broker, fund the account, then place a limit order on the ticker shown in the profile. For stocks listed outside Europe, the W-8BEN form reduces US withholding tax on dividends to 15%. CFD brokers such as Vantage, this site’s go-to broker, also let you take long or short positions through contracts for difference — leverage requires strict risk management.
Practical steps: 1) compare three regulated brokers on trading and currency conversion fees; 2) open the account and verify your identity; 3) fund it by bank transfer; 4) place a first limit order of reasonable size; 5) note the date of the next ex-dividend date; 6) review the position with every earnings release. Regular scheduled investments smooth out the risk of bad timing better than any attempt to predict the market.
DBV Technologies Stock FAQ
Where is DBV Technologies listed?
Euronext Paris (DBV) — PEA-eligible.
Does DBV Technologies pay a dividend?
No dividend is currently paid.
Is DBV Technologies PEA-eligible?
Not for the main listing cited: the stock is held in a standard brokerage account — check the PEA eligibility of the European listing where the group has one.
What is the ISIN of DBV Technologies?
FR0010417345
What are the upcoming key dates?
Annual and quarterly results published by the group are the stock’s main catalysts — follow the financial calendar on DBV Technologies’ investor relations website.
This page is provided for information only and does not constitute investment advice. Past performance is not indicative of future results; any stock market investment carries a risk of capital loss.
